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Quantitative reverse transcription PCR (qRT-PCR) is the diagnostic standard for severe 
acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), the causative agent of coronavirus disease 
(COVID-19) (1). Testing usually is conducted on 
upper respiratory specimens collected using swabs 
(1–3). However, this method requires multiple sam-
ples and has a low sensitivity (4). Swab sampling 
can cause patients to cough or sneeze, uncomfort-
able reactions that might also increase transmis-
sion risks to healthcare workers (A. Wyllie et al., 
unpub. data, https://doi.org/10.1101/2020.04.16.2
0067835). Sampling technique proficiency also var-
ies, especially during self-sampling (A. Wyllie et 
al., unpub. data, https://doi.org/10.1101/2020.0
4.16.20067835), which can result in false negatives. 
Furthermore, shortages of swabs, transport media, 
and personal protective equipment limit healthcare 
capacity to conduct SARS-CoV-2 tests that rely on 
swab sampling.
Saliva sampling is a noninvasive alternative to up-
per respiratory swabbing. We compared paired self-col-
lected saliva samples with healthcare worker–collected 
nasal and throat swab specimens from 110 patients with 
suspected SARS-CoV-2 infection. This analysis was 
part of a prospective study (Facilitating a SARS CoV-2 
Test for Rapid Triage) at the Royal Liverpool Univer-
sity and Aintree University Hospitals (Liverpool, UK). 
We recruited participants who had provided written 
informed consent and had COVID-19 symptoms. The 
National Health Service Research Ethics Committee 
(20/SC/0169) approved the study under Integrated Re-
search Application System no. 282147.
Within 24 hours after patient consent, we col-
lected nasal and throat swab specimens containing 1.0 
mL of Amies transport medium (COPAN Diagnos-
tics, https://www.copanusa.com). We also asked par-
ticipants to funnel their saliva into a sterile cryotube 
(SARSTEDT, https://www.sarstedt.com). We immedi-
ately extracted RNA from the swab samples; we stored 
saliva samples at –80°C until processing. We extracted 
viral RNA using the QIAamp Viral RNA Mini Kit (QIA-
GEN, https://www.qiagen.com) and tested 8 µL of ex-
tracted RNA using the genesig Real-Time Coronavirus 
COVID-19 PCR (genesig, https://www.genesig.com). 
We quantified viral loads using the manufacturer’s pos-
itive control (1.67 × 105 copies/µL) as reference.
Of the 110 adults recruited from April through June 
2020, a total of 61 (55.5%) were women. Most partici-
pants were hospitalized; 21 (19.1%) were discharged to 
home directly from the emergency department. Overall, 
12 (10.9%) saliva and 14 (12.7%) nasal and throat swab 
specimens of 110 paired samples tested positive for 
Figure. Viral load (copies/mL) of SARS-CoV-2 RNA recovered 
from paired saliva samples and nasal and throat swab specimens 
from 14 patients with coronavirus disease, United Kingdom, 2020. 
Viral loads are shown on a logarithmic scale. NS, not significant; 
NT, nasal and throat; SARS-CoV-2, severe acute respiratory 
syndrome coronavirus 2.
PCR of upper respiratory specimens is the diagnostic 
standard for severe acute respiratory syndrome corona-
virus 2 infection. However, saliva sampling is an easy al-
ternative to nasal and throat swabbing. We found similar 
viral loads in saliva samples and in nasal and throat swab 
samples from 110 patients with coronavirus disease.
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SARS-CoV-2 RNA. Viral loads for all samples ranged 
from 36 to 3.3 × 106 copies/mL. Overall viral loads were 
similar among all positive samples (Figure).
Insignificant viral load discrepancies existed 
among all positive samples (p = 0.1955 by Wilcoxon 
signed-rank paired test). Two patients tested positive 
(<10 copies/mL) on nasal and throat swab samples 
and negative on saliva samples; the discrepancies 
might have resulted from the different processing 
times of the 2 specimens because freeze-thawing can 
reduce the stability of RNA (5,6).
Saliva sampling can improve SARS-CoV-2 diag-
nostic techniques. Saliva samples are easier to collect 
than nasal and throat samples; the technique is nonin-
vasive, presumably preferred by the participant, and 
does not require sampling proficiency. In addition, 
saliva sampling does not require swabs and trans-
port media, which have limited availability during 
the pandemic. Our technique uses a funnel which, 
although helpful, might not be necessary for sample 
collection. Our study focused on symptomatic hospi-
talized participants; further research is needed on sa-
liva sampling for patients with mild and asymptom-
atic SARS-CoV-2 infection.
Further studies should document the effects of 
storage and transport on RNA and viral loads. Rapid 
processing of saliva samples might benefit patients in 
low- and middle-income countries, where the pandem-
ic is still accelerating and swab availability is limited 
(7). Furthermore, high-income countries can establish 
a cold chain for sample transportation. A cold chain 
could enable home sampling and screening of children 
who have rejected swabbing. It could also streamline 
research studies that require repeat sampling.
As rates of SARS-CoV-2 infection increase, we 
must continue to investigate efficient diagnostic strat-
egies. Easy and effective diagnostic techniques, such 
as saliva sampling, should be evaluated in certified 
clinical laboratories.
This article was preprinted at https://www.medrxiv.org/
content/10.1101/2020.07.09.20149534v1.
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